Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Silence Therapeutics promotes Sedgwick to CEO role; Christély resigns

Silence Therapeutics promotes Sedgwick to CEO role; Christély resigns

Gene silencing specialist Silence Therapeutics (LON:SLN) announced today that Tony Sedgwick has been appointed the new CEO of the company following the resignation of Thomas Christély.

Sedgwick was formerly the chief business officer and his promotion takes effect immediately, the firm said.

Christély has resigned as a director for personal reasons but will ensure a smooth transition, the company added.

The company's chairman Jerry Randall said: "Tony has a great deal of relevant experience gained from the global pharmaceutical industry. He has made a very positive impact on Silence since joining in September last year and has demonstrated the right leadership skills needed as the company continues to gain momentum."

He thanked Christély for his many years of valuable service, on behalf of the board, and wished him well for the future.

New chief executive Sedgwick said that since joining the company, he had been excited about the opportunities ahead.

"We have already strengthened the business development team with the appointment of Dr Georg Buchner who will now take full responsibility for business development.

"The company's pipeline including Atu027 is making good progress and is endorsed by external partners," he said.

He added that in the next few years, he planned to increase the commercial focus of the company.

The company develops siRNAs, which are double-stranded molecules that silence certain genes. These are being developed to be used in targeting multiple disease types, including cancer.

Last month, the company announced a collaboration agreement with
US–based firm miRagen to assess delivery methods for new, micro versions of gene silencing technology to treat serious diseases.

Why Invest In Silence Therapeutics? Read More Here

Register here to be notified of future SLN Company articles
View full SLN profile

Silence Therapeutics Timeline

Newswire
January 18 2016

Related Articles

August 17 2015
With clinical programme either in the throes of recruitment or toward the end of that particular phase, the more meaningful news emanated drug discovery arm.
September 09 2015
The impending return of ImmuCyst, a bladder cancer treatment, following a three year absence is one of the drivers as is a new product, Diclectin.
April 13 2015

Securing this approval has taken longer than expected, but today's announcement represents a major advance, as indicated by the sharp rise in the share price.


© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.